Aclarion Announces Agreement with Weill Cornell Medicine

Rhea-AI Summary

Aclarion (Nasdaq: ACON) announced a commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. A subset of spine patients in an IRB-approved trial (Protocol No. 22-06024915) will be eligible for Nociscan to help identify discogenic low back pain.

The study investigates dose and quantity of concentrated bone marrow aspirate (BMAC) for osteoarthritis and degenerative disc disease, with Nociscan used alongside other diagnostics.

News Market Reaction – ACONW

-7.27%

1 alert

-7.27% News Effect

On the day this news was published, ACONW declined 7.27%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Global cLBP patients: 266 million people Cash & equivalents: $12,850,657 Money market funds: $11,949,908 +5 more

8 metrics

Global cLBP patients 266 million people Worldwide with degenerative spine disease and low back pain

Cash & equivalents $12,850,657 As of Q2 2025 per 10-Q, including cash and equivalents

Money market funds $11,949,908 Portion of cash and equivalents in money market funds, Q2 2025

Q2 2025 revenue $19,319 Quarter ended June 30, 2025; up 76% year-over-year

H1 2025 revenue $38,309 Six months ended June 30, 2025; up 82% year-over-year

Q2 2025 net loss $1.60 million Quarter ended June 30, 2025 per 10-Q

H1 2025 net loss $3.64 million Six months ended June 30, 2025 per 10-Q

Capital raised H1 2025 $20.1 million Public unit offering, two registered directs and warrant exercises

Market Reality Check

Price: $0.0331 Vol: Volume 1,700 is below the...

low vol

$0.0331 Last Close

Volume Volume 1,700 is below the 20-day average of 8,789 ahead of this news. low

Technical Price at $0.039897 was trading near the $0.04 200-day moving average before this announcement.

Peers on Argus

ACONW was up 20.18% while key peers were mixed: ACON up 6.59%, CCLDO and LFMDP d...

1 Up

ACONW was up 20.18% while key peers were mixed: ACON up 6.59%, CCLDO and LFMDP down, and ONMDW flat, indicating a stock-specific move rather than a broad sector shift.

Historical Context

5 past events · Latest: Mar 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 19	Rights plan adoption	Neutral	+0.3%	Limited duration stockholder rights plan adopted, expiring in one year.
Mar 19	Strategy update	Positive	+0.3%	CEO letter outlining Nociscan adoption goals and 2026 clinical catalysts.
Mar 17	Conference participation	Positive	+28.7%	ROTH Conference meetings to discuss Nociscan progress and strong balance sheet.
Mar 12	Conference attendance	Positive	+8.1%	CEO attending LSI USA 2026 to meet investors and potential partners.
Feb 05	Shareholder letter	Positive	+3.1%	Chairman letter detailing CLARITY trial plans and extended cash runway.

Pattern Detected

Recent corporate and investor-relations news has often coincided with positive price reactions, especially around conferences and strategic updates.

Recent Company History

Over the last few months, Aclarion highlighted shareholder communications, investor conferences, and strategic priorities. A March 2026 shareholder letter and CEO updates emphasized Nociscan adoption, 2026 catalysts, and a cash runway into 2028. Participation in the 38th Annual ROTH Conference and LSI USA 2026 supported investor outreach and partner engagement. The newly announced Weill Cornell Medicine agreement fits this trajectory of expanding Nociscan’s clinical footprint and building clinical evidence alongside ongoing trials and investor-focused activities.

Market Pulse Summary

The stock moved -7.3% in the session following this news. A negative reaction despite this collabora...

Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite this collaborative trial announcement would fit a pattern where broader concerns, such as past losses or capital needs, outweighed positive operational progress. While the Weill Cornell Medicine agreement expands clinical use of Nociscan, the company’s prior filings highlighted ongoing net losses and relatively small revenue. In such a scenario, market focus may have shifted to balance sheet durability and execution risks rather than the long-term promise of new clinical data.

Key Terms

bone marrow aspirate stem cell concentrate, bmac, degenerative disc disease, osteoarthritis, +3 more

7 terms

bone marrow aspirate stem cell concentrate medical

"The trial is entitled “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC)..."

A bone marrow aspirate stem cell concentrate is a medical product made by drawing a small amount of bone marrow, separating and concentrating the stem and other repair cells, and preparing them for therapeutic use. Think of it like collecting seeds from fruit and concentrating them for planting: the process boosts the number of repair cells in a small dose. For investors, it matters because its clinical effectiveness, manufacturing consistency, and regulatory status drive market potential, reimbursement and commercialization risks.

bmac medical

"Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease..."

Bone marrow aspirate concentrate (BMAC) is a medical product made by spinning a small sample of a patient’s bone marrow to concentrate stem cells and other healing components into a liquid used to help repair tissue, most often in orthopedics. For investors, BMAC matters because its clinical effectiveness, regulatory status and adoption by doctors influence demand, reimbursement and potential revenue for companies that make the devices, clinics or related therapies—think of it as a concentrated ingredient that can change the outcome and market size for certain medical treatments.

degenerative disc disease medical

"for Osteoarthritis and Degenerative Disc Disease,” conducted under IRB Protocol No. 22-06024915."

Degenerative disc disease is the gradual breakdown of the soft, cushion-like discs between spinal bones, which can cause chronic back or neck pain and reduced mobility. Like the worn-out shock absorbers on a car, failing discs lead to compensating repairs and replacements, creating sustained demand for treatments such as medications, medical devices, surgeries and rehabilitation; that demand, regulatory approvals and long-term care costs are what make the condition important to investors.

osteoarthritis medical

"used for the treatment of osteoarthritis and/or Degenerative Disc Disease in the spine..."

A chronic joint condition in which the protective cushioning (cartilage) between bones gradually breaks down, causing pain, stiffness and reduced mobility—think of joints like shock absorbers that wear out over time. It matters to investors because it represents a large, predictable market for medicines, surgical devices and long‑term care; clinical trial results, regulatory decisions, reimbursement and new treatments can significantly affect sales, costs and valuation in healthcare-related companies.

irb protocol regulatory

"Degenerative Disc Disease,” conducted under IRB Protocol No. 22-06024915."

An IRB protocol is the written plan that describes how a medical study will be run, reviewed and monitored to protect the safety and rights of participants. Think of it as a rulebook and step‑by‑step checklist that an ethics committee must approve before human testing can begin. For investors, an approved IRB protocol matters because it affects whether a trial can start or continue, the regulatory risk and timelines for potential product approval, and the company’s credibility on patient safety.

biomarkers medical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians..."

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

saas technical

"Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians..."

SaaS, or Software as a Service, is a way of delivering computer programs over the internet, allowing users to access and use them through a web browser without needing to install or maintain the software themselves. For investors, it highlights a business model where companies generate recurring revenue by providing ongoing access to their software, often leading to predictable income and growth potential.

AI-generated analysis. Not financial advice.

Expands use of Nociscan in groundbreaking trial

BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine.

The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team led by triple-board certified physician and Principal Investigator, Jaspal Ricky Singh, MD, who has earned a national reputation for innovation and excellence. The trial is entitled “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease,” conducted under IRB Protocol No. 22-06024915.

The purpose of this initial study is to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate (BMAC) used for the treatment of osteoarthritis and/or Degenerative Disc Disease in the spine has an effect on patient-reported functional outcomes and pain. A subset of spine patients, selected per Dr. Singh’s clinical evaluation, will also be eligible for Nociscan.

“Our team takes a comprehensive approach to the treatment of spinal disorders. Our multidisciplinary approach to treat pain includes physical therapy and various interventional techniques,” said Jaspal Ricky Singh, MD, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine and Rehabilitation Medicine Specialist at Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. “Our pioneering research into discogenic low back pain and cBMA (concentrated bone marrow aspirate) is an ideal opportunity to utilize the insights provided by Nociscan.”

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. ¹ Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan can provide critical insights into the location of a patient’s low back pain and improves pain and function when all Nociscan-positive discs are treated.

For more News from Aclarion, please visit: Latest News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com 

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

References:

1. Ravindra VM, Global Spine Journal (2018) 8(8): 784-794, AO Spine.
   

FAQ

What does Aclarion's agreement with Weill Cornell mean for ACON investors?

It expands commercial availability of Nociscan to a major academic center, potentially increasing clinical adoption. According to the company, Nociscan will be used at Weill Cornell and Och Spine in an IRB-approved trial to assess spine patients selected by investigators.

Which trial will use Nociscan at Weill Cornell and what is its focus (ACON)?

The trial is a prospective review of BMAC for osteoarthritis and degenerative disc disease under IRB Protocol No. 22-06024915. According to the company, a subset of spine patients will be eligible for Nociscan to identify painful lumbar discs.

How will Nociscan be used clinically in the Weill Cornell spine study (ACON)?

Nociscan will noninvasively quantify chemical biomarkers to distinguish painful from nonpainful lumbar discs. According to the company, investigators will use Nociscan alongside other diagnostics to inform treatment of Nociscan-positive discs.

Who is the principal investigator for the Weill Cornell trial involving Aclarion's Nociscan (ACON)?

The trial is led by Jaspal Ricky Singh, MD, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine. According to the company, Dr. Singh will select eligible spine patients for Nociscan assessment in the BMAC study.

Does Aclarion claim Nociscan improves outcomes when used to guide treatment (ACON)?

The company states Nociscan can improve pain and function when all Nociscan-positive discs are treated. According to the company, Nociscan provides objective chemical biomarker data to help locate discogenic sources of low back pain.